Phase 3 Double-blind Multicenter Randomized Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Biktarvy® [Bictegravir/Emtricitabine/Tenofovir Alafenamide] in Virologically Suppressed People With HIV-1 [ARTISTRY 2] (NCT06333808)
ARTISTRY-2
This trial is No longer recruiting
Registration number NCT06333808
Program & service
This trial is being run with the Infectious Diseases service, and as part of the Infectious Diseases program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor James McMahon
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR